form_type
stringclasses 2
values | accession_number
stringlengths 20
20
| filing_date
stringlengths 14
14
| quarter_ending
stringclasses 172
values | company_name
stringlengths 5
54
| text
stringlengths 101
2.42k
| entities
listlengths 1
18
|
|---|---|---|---|---|---|---|
10-Q | 0000002969-23-000014 | 20230202103415 | 20221231 | Air Products & Chemicals, Inc. | $25 in the first three months of fiscal year 2023. The impact of changes in estimates in the first three months of fiscal year 2022 was not material. | [
{
"currency_/_unit": "USD",
"end_character": 3,
"end_date_for_period": "2022-12-31",
"label": "ebit",
"start_character": 1,
"start_date_for_period": "2022-10-01",
"value": -25000000
}
] |
10-Q | 0000943819-23-000003 | 20230126180953 | 20221231 | RESMED INC | We lease Sleep and Respiratory Care medical devices to customers primarily as a means to comply with local health insurer requirements in certain foreign geographies. Device rental contracts include operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. Operating lease revenue was $20.4 million and $44.1 million for the three and six months ended December 31, 2022 and $24.4 million and $49.6 million for the three and six months ended December 31, 2021. | [
{
"currency_/_unit": "USD",
"end_character": 561,
"end_date_for_period": "2022-12-31",
"label": "revenues",
"start_character": 557,
"start_date_for_period": "2022-10-01",
"value": 20400000
},
{
"currency_/_unit": "USD",
"end_character": 579,
"end_date_for_period": "2022-12-31",
"label": "revenues",
"start_character": 575,
"start_date_for_period": "2022-07-01",
"value": 44100000
},
{
"currency_/_unit": "USD",
"end_character": 650,
"end_date_for_period": "2021-12-31",
"label": "revenues",
"start_character": 646,
"start_date_for_period": "2021-10-01",
"value": 24400000
},
{
"currency_/_unit": "USD",
"end_character": 668,
"end_date_for_period": "2021-12-31",
"label": "revenues",
"start_character": 664,
"start_date_for_period": "2021-07-01",
"value": 49600000
}
] |
10-Q | 0000046619-23-000052 | 20230301152604 | 20230131 | HEICO CORP | The allocation of the total consideration to the tangible and identifiable intangible assets acquired and liabilities and noncontrolling interests assumed is preliminary until the Company obtains final information regarding their fair values. The primary items that generated the goodwill recognized were the premiums paid by the Company for the future earnings potential of Exxelia and the value of its assembled workforce that do not qualify for separate recognition, however, benefit both the Company and the noncontrolling interest holders. The fair value of the noncontrolling interests were determined based on the consideration paid by the Company for its controlling ownership interest adjusted for a lack of control that a market participant would consider when estimating the fair value of the noncontrolling interest. The amortization period of the customer relationships, intellectual property and trade name acquired is 18 years, 16 years and indefinite, respectively. Acquisition costs associated with the purchase of Exxelia totaled $5.1 million for the three months ended January 31, 2023 and were recorded as a component of SG&A expenses in the Company's Condensed Consolidated Statement of Operations. The operating results of Exxelia were included in the Company’s results of operations from the effective acquisition date. For the three months ended January 31, 2023, the Company's consolidated net sales includes $15.0 million from the acquisition of Exxelia, and the acquisition did not have a material impact on net income attributable to HEICO. | [
{
"currency_/_unit": "USD",
"end_character": 1056,
"end_date_for_period": "2023-01-31",
"label": "XBRL-OOS",
"start_character": 1053,
"start_date_for_period": "2023-01-31",
"value": 5100000
},
{
"currency_/_unit": "USD",
"end_character": 1445,
"end_date_for_period": "2023-01-31",
"label": "revenues",
"start_character": 1441,
"start_date_for_period": "2022-11-01",
"value": 15000000
}
] |
10-Q | 0001618921-23-000005 | 20230105160936 | 20221130 | Walgreens Boots Alliance, Inc. | Due to the anti-dilutive effect resulting from the reported net loss, an incremental 2.6 million of potentially dilutive securities were omitted from the calculation of weighted-average common shares outstanding for the three months ended November 30, 2022. | [
{
"currency_/_unit": "shares",
"end_character": 88,
"end_date_for_period": "2022-11-30",
"label": "eps",
"start_character": 85,
"start_date_for_period": "2022-09-01",
"value": 2600000
}
] |
10-Q | 0001140361-23-005884 | 20230210144630 | 20221231 | Home Federal Bancorp, Inc. of Louisiana | Earnings per share are computed based upon the weighted average number of
common shares outstanding during the period. The Company’s basic and diluted earnings per share were $1.10 and $1.05, respectively, for the six months ended December 31, 2022 compared to basic and diluted earnings per share of $0.79 and $0.73, respectively, for
the six months ended December 31, 2021. The Company’s basic and diluted earnings per share were $0.57 and $0.55, respectively, for the three months ended December 31, 2022 compared to basic and diluted earnings per share of $0.36 and $0.34, respectively, for the three months ended December 31, 2021.
| [
{
"currency_/_unit": null,
"end_character": 194,
"end_date_for_period": "2022-12-31",
"label": "eps",
"start_character": 190,
"start_date_for_period": "2022-07-01",
"value": 1.1
},
{
"currency_/_unit": null,
"end_character": 204,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 200,
"start_date_for_period": "2022-07-01",
"value": 1.05
},
{
"currency_/_unit": null,
"end_character": 320,
"end_date_for_period": "2021-12-31",
"label": "eps",
"start_character": 316,
"start_date_for_period": "2021-07-01",
"value": 0.79
},
{
"currency_/_unit": null,
"end_character": 330,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 326,
"start_date_for_period": "2021-07-01",
"value": 0.73
},
{
"currency_/_unit": null,
"end_character": 466,
"end_date_for_period": "2022-12-31",
"label": "eps",
"start_character": 462,
"start_date_for_period": "2022-10-01",
"value": 0.5700000000000001
},
{
"currency_/_unit": null,
"end_character": 476,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 472,
"start_date_for_period": "2022-10-01",
"value": 0.55
},
{
"currency_/_unit": null,
"end_character": 594,
"end_date_for_period": "2021-12-31",
"label": "eps",
"start_character": 590,
"start_date_for_period": "2021-10-01",
"value": 0.36
},
{
"currency_/_unit": null,
"end_character": 604,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 600,
"start_date_for_period": "2021-10-01",
"value": 0.34
}
] |
10-Q | 0001140361-23-005884 | 20230210144630 | 20221231 | Home Federal Bancorp, Inc. of Louisiana | Earnings per share are computed based upon the weighted average number of
common shares outstanding during the period. The Company’s basic and diluted earnings per share were $1.10 and $1.05, respectively, for the six months ended December 31, 2022 compared to basic and diluted earnings per share of $0.79 and $0.73, respectively, for
the six months ended December 31, 2021. The Company’s basic and diluted earnings per share were $0.57 and $0.55, respectively, for the three months ended December 31, 2022 compared to basic and diluted earnings per share of $0.36 and $0.34, respectively, for the three months ended December 31, 2021. | [
{
"currency_/_unit": null,
"end_character": 194,
"end_date_for_period": "2022-12-31",
"label": "eps",
"start_character": 190,
"start_date_for_period": "2022-07-01",
"value": 1.1
},
{
"currency_/_unit": null,
"end_character": 204,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 200,
"start_date_for_period": "2022-07-01",
"value": 1.05
},
{
"currency_/_unit": null,
"end_character": 320,
"end_date_for_period": "2021-12-31",
"label": "eps",
"start_character": 316,
"start_date_for_period": "2021-07-01",
"value": 0.79
},
{
"currency_/_unit": null,
"end_character": 330,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 326,
"start_date_for_period": "2021-07-01",
"value": 0.73
},
{
"currency_/_unit": null,
"end_character": 466,
"end_date_for_period": "2022-12-31",
"label": "eps",
"start_character": 462,
"start_date_for_period": "2022-10-01",
"value": 0.5700000000000001
},
{
"currency_/_unit": null,
"end_character": 476,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 472,
"start_date_for_period": "2022-10-01",
"value": 0.55
},
{
"currency_/_unit": null,
"end_character": 594,
"end_date_for_period": "2021-12-31",
"label": "eps",
"start_character": 590,
"start_date_for_period": "2021-10-01",
"value": 0.36
},
{
"currency_/_unit": null,
"end_character": 604,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 600,
"start_date_for_period": "2021-10-01",
"value": 0.34
}
] |
10-Q | 0000900075-23-000010 | 20230224160556 | 20230131 | COPART INC | The cost of the leased space as of January 31, 2023 and July 31, 2022 was $51.2 million and $51.2 million, respectively. The accumulated depreciation associated with the leased assets as of January 31, 2023 and July 31, 2022 was $3.3 million and $2.8 million, respectively. Both the leased assets and accumulated depreciation are included in Property and equipment, net on the consolidated balance sheet. Rental income from these operating leases was $4.1 million and $3.7 million for the three months ended January 31, 2023 and 2022, respectively, and $8.3 million and $7.2 million for the six months ended January 31, 2023 and 2022, respectively, and is included within Service revenues on the consolidated statements of income. | [
{
"currency_/_unit": "USD",
"end_character": 79,
"end_date_for_period": "2023-01-31",
"label": "XBRL-OOS",
"start_character": 75,
"start_date_for_period": "2023-01-31",
"value": 51200000
},
{
"currency_/_unit": "USD",
"end_character": 97,
"end_date_for_period": "2023-01-31",
"label": "XBRL-OOS",
"start_character": 93,
"start_date_for_period": "2023-01-31",
"value": 51200000
},
{
"currency_/_unit": "USD",
"end_character": 233,
"end_date_for_period": "2023-01-31",
"label": "XBRL-OOS",
"start_character": 230,
"start_date_for_period": "2023-01-31",
"value": 3300000
},
{
"currency_/_unit": "USD",
"end_character": 250,
"end_date_for_period": "2022-07-31",
"label": "XBRL-OOS",
"start_character": 247,
"start_date_for_period": "2022-07-31",
"value": 2800000
},
{
"currency_/_unit": "USD",
"end_character": 455,
"end_date_for_period": "2023-01-31",
"label": "revenues",
"start_character": 452,
"start_date_for_period": "2022-11-01",
"value": 4099999.9999999995
},
{
"currency_/_unit": "USD",
"end_character": 472,
"end_date_for_period": "2022-01-31",
"label": "revenues",
"start_character": 469,
"start_date_for_period": "2021-11-01",
"value": 3700000
},
{
"currency_/_unit": "USD",
"end_character": 557,
"end_date_for_period": "2023-01-31",
"label": "revenues",
"start_character": 554,
"start_date_for_period": "2022-08-01",
"value": 8300000.000000001
},
{
"currency_/_unit": "USD",
"end_character": 574,
"end_date_for_period": "2022-01-31",
"label": "revenues",
"start_character": 571,
"start_date_for_period": "2021-08-01",
"value": 7200000
}
] |
10-Q | 0001062993-23-004189 | 20230221144257 | 20221231 | W&E Source Corp. | As reflected in the accompanying consolidated financial statements, the Company had accumulated deficits of $1,364,957 and $1,327,434 as of December 31, 2022 and June 30, 2022, and net losses of $37,523 and $22,610, respectively, for the six months ended December 31, 2022 and 2021. The Company currently has business activities to generate funds for its own operations, however, has not yet achieved profitable operations. These factors raise substantial doubt about our ability to continue as a going concern. The Company's ability to continue as a going concern is dependent on its ability to raise additional capital and implement its business plan. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. | [
{
"currency_/_unit": "USD",
"end_character": 118,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 109,
"start_date_for_period": "2022-12-31",
"value": -1364957
},
{
"currency_/_unit": "USD",
"end_character": 133,
"end_date_for_period": "2022-06-30",
"label": "XBRL-OOS",
"start_character": 124,
"start_date_for_period": "2022-06-30",
"value": -1327434
},
{
"currency_/_unit": "USD",
"end_character": 202,
"end_date_for_period": "2022-12-31",
"label": "earnings",
"start_character": 196,
"start_date_for_period": "2022-07-01",
"value": -37523
},
{
"currency_/_unit": "USD",
"end_character": 214,
"end_date_for_period": "2021-12-31",
"label": "earnings",
"start_character": 208,
"start_date_for_period": "2021-07-01",
"value": -22610
}
] |
10-Q | 0001062993-23-004189 | 20230221144257 | 20221231 | W&E Source Corp. | As reflected in the accompanying consolidated financial statements, the Company had accumulated deficits of $1,364,957 and $1,327,434 as of December 31, 2022 and June 30, 2022, and net losses of $37,523 and $22,610, respectively, for the six months ended December 31, 2022 and 2021. The Company currently has business activities to generate funds for its own operations, however, has not yet achieved profitable operations. These factors raise substantial doubt about our ability to continue as a going concern. The Company's ability to continue as a going concern is dependent on its ability to raise additional capital and implement its business plan. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. | [
{
"currency_/_unit": "USD",
"end_character": 118,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 109,
"start_date_for_period": "2022-12-31",
"value": -1364957
},
{
"currency_/_unit": "USD",
"end_character": 133,
"end_date_for_period": "2022-06-30",
"label": "XBRL-OOS",
"start_character": 124,
"start_date_for_period": "2022-06-30",
"value": -1327434
},
{
"currency_/_unit": "USD",
"end_character": 202,
"end_date_for_period": "2022-12-31",
"label": "earnings",
"start_character": 196,
"start_date_for_period": "2022-07-01",
"value": -37523
},
{
"currency_/_unit": "USD",
"end_character": 214,
"end_date_for_period": "2021-12-31",
"label": "earnings",
"start_character": 208,
"start_date_for_period": "2021-07-01",
"value": -22610
}
] |
10-Q | 0001321741-23-000004 | 20230201161151 | 20221231 | GLADSTONE INVESTMENT CORPORATION\DE | From time to time, Gladstone Securities provides services, such as investment banking and due diligence services, to certain of our portfolio companies, for which it receives a fee. Any such fees paid by portfolio companies to Gladstone Securities do not impact the fees we pay to the Adviser or the non-contractual, unconditional, and irrevocable credits against the base management fee. During the three and nine months ended December 31, 2022, the fees received by Gladstone Securities from our portfolio companies totaled $0.3 million and $1.6 million, respectively. During the three and nine months ended December 31, 2021, the fees received by Gladstone Securities from our portfolio companies totaled $2.8 million and $3.2 million, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 530,
"end_date_for_period": "2022-12-31",
"label": "revenues",
"start_character": 527,
"start_date_for_period": "2022-10-01",
"value": 300000
},
{
"currency_/_unit": "USD",
"end_character": 547,
"end_date_for_period": "2022-12-31",
"label": "revenues",
"start_character": 544,
"start_date_for_period": "2022-04-01",
"value": 1600000
},
{
"currency_/_unit": "USD",
"end_character": 712,
"end_date_for_period": "2021-12-31",
"label": "revenues",
"start_character": 709,
"start_date_for_period": "2021-10-01",
"value": 2800000
},
{
"currency_/_unit": "USD",
"end_character": 729,
"end_date_for_period": "2021-12-31",
"label": "revenues",
"start_character": 726,
"start_date_for_period": "2021-04-01",
"value": 3200000
}
] |
10-Q | 0000010048-23-000006 | 20230213160942 | 20221231 | BARNWELL INDUSTRIES INC | The following table presents certain financial information related to Barnwell’s reporting segments. All revenues reported are from external customers with no intersegment sales or transfers. | [
{
"currency_/_unit": "USD",
"end_character": 158,
"end_date_for_period": "2022-12-31",
"label": "revenues",
"start_character": 156,
"start_date_for_period": "2022-10-01",
"value": 0
}
] |
10-Q | 0001650372-23-000009 | 20230203160640 | 20221231 | Atlassian Corp | The Company reported an income tax provision of $100.5 million on pretax loss of $104.5 million and an income tax provision of $108.5 million on pretax loss of $110.2 million for the three and six months ended December 31, 2022, respectively, as compared to an income tax provision of $2.1 million on pretax loss of $20.2 million and an income tax provision of $2.7 million on pretax loss of $430.8 million for the three and six months ended December 31, 2021, respectively. The income tax provision for the three and six months ended December 31, 2022 reflects an increase in tax expense primarily attributable to the recognition of a reserve for uncertain tax positions, overall growth in foreign jurisdictions associated with an increase in profit and non-deductible stock-based compensation. The Company’s effective tax rate substantially differed from the U.S. statutory income tax rate of 21.0% primarily due to the recognition of a reserve for uncertain tax positions, different tax rates, non-deductible stock-based compensation in foreign jurisdictions, in addition to full valuation allowances in the U.S. and Australia. | [
{
"currency_/_unit": "USD",
"end_character": 54,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 49,
"start_date_for_period": "2022-10-01",
"value": 100500000
},
{
"currency_/_unit": "USD",
"end_character": 87,
"end_date_for_period": "2022-12-31",
"label": "earnings",
"start_character": 82,
"start_date_for_period": "2022-10-01",
"value": -104500000
},
{
"currency_/_unit": "USD",
"end_character": 133,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 128,
"start_date_for_period": "2022-07-01",
"value": 108500000
},
{
"currency_/_unit": "USD",
"end_character": 166,
"end_date_for_period": "2022-12-31",
"label": "earnings",
"start_character": 161,
"start_date_for_period": "2022-07-01",
"value": -110200000
},
{
"currency_/_unit": "USD",
"end_character": 289,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 286,
"start_date_for_period": "2021-10-01",
"value": 2100000
},
{
"currency_/_unit": "USD",
"end_character": 321,
"end_date_for_period": "2021-12-31",
"label": "earnings",
"start_character": 317,
"start_date_for_period": "2021-10-01",
"value": -20200000
},
{
"currency_/_unit": "USD",
"end_character": 365,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 362,
"start_date_for_period": "2021-07-01",
"value": 2700000
},
{
"currency_/_unit": "USD",
"end_character": 398,
"end_date_for_period": "2021-12-31",
"label": "earnings",
"start_character": 393,
"start_date_for_period": "2021-07-01",
"value": -430800000
}
] |
10-Q | 0001493152-23-007434 | 20230313164417 | 20230131 | Ocean Power Technologies, Inc. | Contract
liabilities consist of amounts invoiced to customers in excess of revenue recognized. The increase in contract liabilities is primarily
due to payments received for the following; $1.0 million related to future grant revenue and $0.4 million for future sales revenue during
the nine months ended January 31, 2023 for which revenue has not been recognized. | [
{
"currency_/_unit": "USD",
"end_character": 193,
"end_date_for_period": "2023-01-31",
"label": "revenues",
"start_character": 190,
"start_date_for_period": "2022-05-01",
"value": 1000000
},
{
"currency_/_unit": "USD",
"end_character": 242,
"end_date_for_period": "2023-01-31",
"label": "revenues",
"start_character": 239,
"start_date_for_period": "2022-05-01",
"value": 400000
}
] |
10-Q | 0001062993-23-007172 | 20230317160540 | 20230131 | Rise Gold Corp. | The Company is in the early stages of exploration and, as is common with any exploration company, it raises financing for its acquisition activities. The accompanying condensed consolidated interim financial statements have been prepared on the going concern basis, which presumes that the Company will continue operations for the foreseeable future and will be able to realize assets and discharge liabilities in the normal course of business. The Company has incurred a loss of $2,146,016 for the six-month period ended January 31, 2023 and has accumulated a deficit of $25,154,620. The ability of the Company to continue as a going concern is dependent on the Company's ability to maintain continued support from its shareholders and creditors and to raise additional capital and implement its business plan. There is no assurance that the Company will be able to obtain adequate financing in the future or that such financing will be on terms advantageous to the Company. These events and conditions cast significant doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. | [
{
"currency_/_unit": "USD",
"end_character": 490,
"end_date_for_period": "2023-01-31",
"label": "earnings",
"start_character": 481,
"start_date_for_period": "2022-08-01",
"value": -2146016
},
{
"currency_/_unit": "USD",
"end_character": 583,
"end_date_for_period": "2023-01-31",
"label": "XBRL-OOS",
"start_character": 573,
"start_date_for_period": "2023-01-31",
"value": -25154620
}
] |
10-Q | 0001062993-23-007172 | 20230317160540 | 20230131 | Rise Gold Corp. | The Company is in the early stages of exploration and, as is common with any exploration company, it raises financing for its acquisition activities. The accompanying condensed consolidated interim financial statements have been prepared on the going concern basis, which presumes that the Company will continue operations for the foreseeable future and will be able to realize assets and discharge liabilities in the normal course of business. The Company has incurred a loss of $2,146,016 for the six-month period ended January 31, 2023 and has accumulated a deficit of $25,154,620. The ability of the Company to continue as a going concern is dependent on the Company's ability to maintain continued support from its shareholders and creditors and to raise additional capital and implement its business plan. There is no assurance that the Company will be able to obtain adequate financing in the future or that such financing will be on terms advantageous to the Company. These events and conditions cast significant doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. | [
{
"currency_/_unit": "USD",
"end_character": 490,
"end_date_for_period": "2023-01-31",
"label": "earnings",
"start_character": 481,
"start_date_for_period": "2022-08-01",
"value": -2146016
},
{
"currency_/_unit": "USD",
"end_character": 583,
"end_date_for_period": "2023-01-31",
"label": "XBRL-OOS",
"start_character": 573,
"start_date_for_period": "2023-01-31",
"value": -25154620
}
] |
10-Q | 0001493152-23-007598 | 20230314160802 | 20230131 | Vitro Biopharma, Inc. | The
accompanying financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going
concern. The Company has incurred net losses of approximately $1.2 million for the three months ended January 31, 2023 and approximately
$6.9 million for the year ended October 31, 2022. The Company had a working capital deficit of approximately $38,000 as of January 31,
2023. In addition, the revenues of the Company do not provide adequate working capital for the Company to sustain its current and planned
business operations. | [
{
"currency_/_unit": "USD",
"end_character": 205,
"end_date_for_period": "2023-01-31",
"label": "earnings",
"start_character": 202,
"start_date_for_period": "2022-11-01",
"value": -1200000
},
{
"currency_/_unit": "USD",
"end_character": 280,
"end_date_for_period": "2022-10-31",
"label": "earnings",
"start_character": 277,
"start_date_for_period": "2021-11-01",
"value": -6900000
}
] |
10-Q | 0001493152-23-001517 | 20230117061929 | 20221130 | Norris Industries, Inc. | The
Company has incurred continuing losses since 2016, including a loss of $498,947 and $465,117 for the fiscal year ended February 28, 2022,
and the nine-month ended November 30, 2022, respectively. During the nine months ended November 30, 2022, the Company incurred cash losses
of approximately $162,000 from its operating activities. As of November 30, 2022, the Company had a cash balance of approximately $177,000
and working capital of approximately negative $4,100,000. | [
{
"currency_/_unit": "USD",
"end_character": 83,
"end_date_for_period": "2022-02-28",
"label": "earnings",
"start_character": 76,
"start_date_for_period": "2021-03-01",
"value": 498947
},
{
"currency_/_unit": "USD",
"end_character": 96,
"end_date_for_period": "2022-11-30",
"label": "earnings",
"start_character": 89,
"start_date_for_period": "2022-03-01",
"value": 465117
},
{
"currency_/_unit": "USD",
"end_character": 476,
"end_date_for_period": "2022-11-30",
"label": "XBRL-OOS",
"start_character": 467,
"start_date_for_period": "2022-11-30",
"value": -4100000
}
] |
10-Q | 0001776932-23-000005 | 20230202160625 | 20221224 | MedMen Enterprises, Inc. | As of December 24, 2022, the Company had cash and cash equivalents of $15,605,362 and working capital deficit of $137,433,003. The Company has incurred net losses from continuing operations of $15,086,276 and $39,426,853 for the three and six months ended December 24, 2022, respectively. The conditions described above raise substantial doubt with respect to the Company’s ability to meet its obligations for at least one year from the issuance of these Condensed Consolidated Financial Statements, and therefore, to continue as a going concern. | [
{
"currency_/_unit": "USD",
"end_character": 81,
"end_date_for_period": "2022-12-24",
"label": "XBRL-OOS",
"start_character": 71,
"start_date_for_period": "2022-12-24",
"value": 15605362
},
{
"currency_/_unit": "USD",
"end_character": 125,
"end_date_for_period": "2022-12-24",
"label": "XBRL-OOS",
"start_character": 114,
"start_date_for_period": "2022-12-24",
"value": -137433003
},
{
"currency_/_unit": "USD",
"end_character": 205,
"end_date_for_period": "2022-12-24",
"label": "earnings",
"start_character": 195,
"start_date_for_period": "2022-09-25",
"value": -15086276
},
{
"currency_/_unit": "USD",
"end_character": 221,
"end_date_for_period": "2022-12-24",
"label": "earnings",
"start_character": 211,
"start_date_for_period": "2022-06-26",
"value": -39426853
}
] |
10-Q | 0001062993-23-005132 | 20230228172527 | 20221231 | ALKALINE WATER Co INC | As a result of the correction, total Revenue decreased from $15,110,400 to $13,100,048 for the three months ended December 31, 2021 and from $44,479,743 to $39,684,465 for the nine months ended December 31, 2021 with a corresponding decrease of Gross Profit from $4,982,256 to $2,971,904 for the three months ended December 31, 2021 and from $14,949,173 to $10,153,895 for the nine months ended December 31, 2021. The correction had no impact on Total operating loss or Net loss for either the three or nine months ended December 31, 2021. | [
{
"currency_/_unit": "USD",
"end_character": 71,
"end_date_for_period": "2021-12-31",
"label": "revenues",
"start_character": 61,
"start_date_for_period": "2021-10-01",
"value": 15110400
},
{
"currency_/_unit": "USD",
"end_character": 86,
"end_date_for_period": "2021-12-31",
"label": "revenues",
"start_character": 76,
"start_date_for_period": "2021-10-01",
"value": 13100048
},
{
"currency_/_unit": "USD",
"end_character": 152,
"end_date_for_period": "2021-12-31",
"label": "revenues",
"start_character": 142,
"start_date_for_period": "2021-04-01",
"value": 44479743
},
{
"currency_/_unit": "USD",
"end_character": 167,
"end_date_for_period": "2021-12-31",
"label": "revenues",
"start_character": 157,
"start_date_for_period": "2021-04-01",
"value": 39684465
},
{
"currency_/_unit": "USD",
"end_character": 273,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 264,
"start_date_for_period": "2021-10-01",
"value": 4982256
},
{
"currency_/_unit": "USD",
"end_character": 287,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 278,
"start_date_for_period": "2021-10-01",
"value": 2971904
},
{
"currency_/_unit": "USD",
"end_character": 353,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 343,
"start_date_for_period": "2021-04-01",
"value": 14949173
},
{
"currency_/_unit": "USD",
"end_character": 368,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 358,
"start_date_for_period": "2021-04-01",
"value": 10153895
}
] |
10-Q | 0001062993-23-005132 | 20230228172527 | 20221231 | ALKALINE WATER Co INC | As a result of the correction, total Revenue decreased from $15,110,400 to $13,100,048 for the three months ended December 31, 2021 and from $44,479,743 to $39,684,465 for the nine months ended December 31, 2021 with a corresponding decrease of Gross Profit from $4,982,256 to $2,971,904 for the three months ended December 31, 2021 and from $14,949,173 to $10,153,895 for the nine months ended December 31, 2021. The correction had no impact on Total operating loss or Net loss for either the three or nine months ended December 31, 2021. | [
{
"currency_/_unit": "USD",
"end_character": 71,
"end_date_for_period": "2021-12-31",
"label": "revenues",
"start_character": 61,
"start_date_for_period": "2021-10-01",
"value": 15110400
},
{
"currency_/_unit": "USD",
"end_character": 86,
"end_date_for_period": "2021-12-31",
"label": "revenues",
"start_character": 76,
"start_date_for_period": "2021-10-01",
"value": 13100048
},
{
"currency_/_unit": "USD",
"end_character": 152,
"end_date_for_period": "2021-12-31",
"label": "revenues",
"start_character": 142,
"start_date_for_period": "2021-04-01",
"value": 44479743
},
{
"currency_/_unit": "USD",
"end_character": 167,
"end_date_for_period": "2021-12-31",
"label": "revenues",
"start_character": 157,
"start_date_for_period": "2021-04-01",
"value": 39684465
},
{
"currency_/_unit": "USD",
"end_character": 273,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 264,
"start_date_for_period": "2021-10-01",
"value": 4982256
},
{
"currency_/_unit": "USD",
"end_character": 287,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 278,
"start_date_for_period": "2021-10-01",
"value": 2971904
},
{
"currency_/_unit": "USD",
"end_character": 353,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 343,
"start_date_for_period": "2021-04-01",
"value": 14949173
},
{
"currency_/_unit": "USD",
"end_character": 368,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 358,
"start_date_for_period": "2021-04-01",
"value": 10153895
}
] |
10-Q | 0001493152-23-004203 | 20230210083025 | 20221231 | Anebulo Pharmaceuticals, Inc. | Since
inception, the Company’s activities have consisted primarily of performing research and development to advance its product candidates.
The Company is still in the development phase and has not been marketing any developed products to date. Since inception, the Company
has incurred losses, including a net loss of approximately $6.4 million for the six months ended December 31, 2022. As of December 31,
2022, the Company had an accumulated deficit of approximately $51.9 million. The Company expects to continue to generate operating losses.
The Company expects that its cash will be sufficient to fund its operating expenses and capital expenditure requirements through at least
12 months from the issuance date of the financial statements. Until such time, if ever, as the Company can generate substantial product
revenue from sales of any current or future product candidates, the Company expects to seek additional funding in order to reach its
development and commercialization objectives through various potential sources, such as equity and debt financings or through collaboration,
license and development agreements. The Company may not be able to obtain funding or enter into collaboration, license or development
agreements on acceptable terms, or at all. The terms of any funding may be dilutive to or adversely affect the rights of the Company’s
stockholders. If the Company is unable to obtain funding on satisfactory terms, or at all, the Company could be forced to delay, scale
back or eliminate the development of its current or future product candidates or other business. | [
{
"currency_/_unit": "USD",
"end_character": 338,
"end_date_for_period": "2022-12-31",
"label": "earnings",
"start_character": 335,
"start_date_for_period": "2022-07-01",
"value": -6400000
},
{
"currency_/_unit": "USD",
"end_character": 477,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 473,
"start_date_for_period": "2022-12-31",
"value": -51900000
}
] |
10-Q | 0000029644-23-000035 | 20230308142647 | 20230131 | DONALDSON Co INC | Earnings before income taxes for the Life Sciences segment for the six months ended January 31, 2023 were $17.1 million, or 14.0% of net sales, a decrease from 25.9% of net sales for the six months ended January 31, 2022. The decrease was driven by lower disk drive volumes causing a decline in profitability and the expected initial negative earnings impact from the recent acquisitions. | [
{
"currency_/_unit": "USD",
"end_character": 111,
"end_date_for_period": "2023-01-31",
"label": "earnings",
"start_character": 107,
"start_date_for_period": "2022-08-01",
"value": 17100000
}
] |
10-Q | 0001342423-23-000010 | 20230309160445 | 20230131 | Limoneira CO | The proceeds were used to pay down all of the Company’s domestic debt except the AgWest Farm Credit $40,000,000 non-revolving line of credit. The Northern Properties component, including an allocation of interest expense related to the debt directly repaid through the transaction, had a pretax loss of $1,667,000 and $2,720,000 for the three months ended January 31, 2023 and 2022, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 111,
"end_date_for_period": "2023-01-31",
"label": "XBRL-OOS",
"start_character": 101,
"start_date_for_period": "2023-01-31",
"value": 40000000
},
{
"currency_/_unit": "USD",
"end_character": 313,
"end_date_for_period": "2023-01-31",
"label": "earnings",
"start_character": 304,
"start_date_for_period": "2022-11-01",
"value": -1667000
},
{
"currency_/_unit": "USD",
"end_character": 328,
"end_date_for_period": "2022-01-31",
"label": "earnings",
"start_character": 319,
"start_date_for_period": "2021-11-01",
"value": -2720000
}
] |
10-Q | 0001342423-23-000010 | 20230309160445 | 20230131 | Limoneira CO | Revenues related to rental operations are included in “Corporate and Other.” Other agribusiness revenues consisted of oranges of $1,152,000 and specialty citrus and other crops of $1,247,000 for the three months ended January 31, 2023. Other agribusiness revenues consisted of oranges of $873,000 and specialty citrus and other crops of $876,000 for the three months ended January 31, 2022. | [
{
"currency_/_unit": "USD",
"end_character": 139,
"end_date_for_period": "2023-01-31",
"label": "revenues",
"start_character": 130,
"start_date_for_period": "2022-11-01",
"value": 1152000
},
{
"currency_/_unit": "USD",
"end_character": 190,
"end_date_for_period": "2023-01-31",
"label": "revenues",
"start_character": 181,
"start_date_for_period": "2022-11-01",
"value": 1247000
},
{
"currency_/_unit": "USD",
"end_character": 296,
"end_date_for_period": "2022-01-31",
"label": "revenues",
"start_character": 289,
"start_date_for_period": "2021-11-01",
"value": 873000
},
{
"currency_/_unit": "USD",
"end_character": 345,
"end_date_for_period": "2022-01-31",
"label": "revenues",
"start_character": 338,
"start_date_for_period": "2021-11-01",
"value": 876000
}
] |
10-Q | 0001681622-23-000013 | 20230131161008 | 20221230 | Varex Imaging Corp | For the three months ended December 30, 2022, the Company recognized income tax expense of $2.2 million on $5.4 million of pre-tax income. For the three months ended December 31, 2021, the Company recognized income tax expense of $1.7 million on $3.3 million of pre-tax income. The Company is unable to recognize a tax benefit for pre-tax book losses in certain foreign jurisdictions but has recognized tax expense for profitable foreign jurisdictions. | [
{
"currency_/_unit": "USD",
"end_character": 95,
"end_date_for_period": "2022-12-30",
"label": "XBRL-OOS",
"start_character": 92,
"start_date_for_period": "2022-10-01",
"value": 2200000
},
{
"currency_/_unit": "USD",
"end_character": 111,
"end_date_for_period": "2022-12-30",
"label": "earnings",
"start_character": 108,
"start_date_for_period": "2022-10-01",
"value": 5400000
},
{
"currency_/_unit": "USD",
"end_character": 234,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 231,
"start_date_for_period": "2021-10-02",
"value": 1700000
},
{
"currency_/_unit": "USD",
"end_character": 250,
"end_date_for_period": "2021-12-31",
"label": "earnings",
"start_character": 247,
"start_date_for_period": "2021-10-02",
"value": 3300000
}
] |
10-Q | 0001607062-23-000036 | 20230126101957 | 20221231 | United Express Inc. | We
have received $114,342 operating revenues for the three months period ended December 31,2022 and 300,564 for the three months period ended
December 31,2021. Recorded revenues were generated from dispatch service and logistics. The Company is currently devoting substantially
all of its present efforts to securing and establishing the business indicated above. | [
{
"currency_/_unit": "USD",
"end_character": 25,
"end_date_for_period": "2022-12-31",
"label": "revenues",
"start_character": 18,
"start_date_for_period": "2022-10-01",
"value": 114342
},
{
"currency_/_unit": "USD",
"end_character": 107,
"end_date_for_period": "2021-12-31",
"label": "revenues",
"start_character": 100,
"start_date_for_period": "2021-10-01",
"value": 300564
}
] |
10-Q | 0001607062-23-000036 | 20230126101957 | 20221231 | United Express Inc. | For
the six months period ended December 31, 2022, the Company had a Stockholders’ Equity of $7,112 and net loss $624 from operations.
For the six months period ended December 31, 2021, the Company had a Stockholders’ Equity of $65,333 and net profit $14,784 from
operations. | [
{
"currency_/_unit": "USD",
"end_character": 258,
"end_date_for_period": "2021-12-31",
"label": "earnings",
"start_character": 252,
"start_date_for_period": "2021-07-01",
"value": 14784
}
] |
10-Q | 0001636050-23-000007 | 20230214064613 | 20221231 | Sio Gene Therapies Inc. | For the nine months ended December 31, 2022 and the fiscal year ended March 31, 2022, the Company incurred net losses of $15.5 million and $71.9 million, respectively. As of December 31, 2022, the Company’s cash and cash equivalents totaled $46.1 million and its accumulated deficit was $878.5 million. The Company estimates that its current cash and cash equivalents balance is sufficient to support operations beyond the twelve month period following the date that these unaudited condensed consolidated financial statements were issued. These estimates are based on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects. | [
{
"currency_/_unit": "USD",
"end_character": 126,
"end_date_for_period": "2022-12-31",
"label": "earnings",
"start_character": 122,
"start_date_for_period": "2022-04-01",
"value": -15500000
},
{
"currency_/_unit": "USD",
"end_character": 144,
"end_date_for_period": "2022-03-31",
"label": "earnings",
"start_character": 140,
"start_date_for_period": "2021-04-01",
"value": -71900000
},
{
"currency_/_unit": "USD",
"end_character": 246,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 242,
"start_date_for_period": "2022-12-31",
"value": 46100000
},
{
"currency_/_unit": "USD",
"end_character": 293,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 288,
"start_date_for_period": "2022-12-31",
"value": -878500000
}
] |
10-Q | 0001520138-23-000034 | 20230117150036 | 20221130 | FingerMotion, Inc. | We
recorded $21,241,015 and $17,285,302 in revenue, respectively, for the nine months ended November 30, 2022 and 2021. | [
{
"currency_/_unit": "USD",
"end_character": 23,
"end_date_for_period": "2022-11-30",
"label": "revenues",
"start_character": 13,
"start_date_for_period": "2022-03-01",
"value": 21241015
},
{
"currency_/_unit": "USD",
"end_character": 39,
"end_date_for_period": "2021-11-30",
"label": "revenues",
"start_character": 29,
"start_date_for_period": "2021-03-01",
"value": 17285302
}
] |
10-Q | 0001601046-23-000015 | 20230303160827 | 20230131 | Keysight Technologies, Inc. | Beginning in fiscal year 2023, to align the presentation of revenue with the manner in which management reviews such information, the presentation of "products" and "services and other" revenue and the presentation of "costs and expenses" in the condensed consolidated statement of operations were reclassified to move revenue and costs and expenses primarily related to bundled licenses and KeysightCare services from products to services and other. This resulted in reclassification of $20 million from "products" revenue to "services and other" revenue and $3 million from "cost of products" to "cost of services and other" for the three months ended January 31, 2022 to conform to the current presentation. This change had no impact on reported total revenue, income from operations and net income in our condensed consolidated statement of operations. | [
{
"currency_/_unit": "USD",
"end_character": 27,
"end_date_for_period": "2022-01-31",
"label": "revenues",
"start_character": 25,
"start_date_for_period": "2021-11-01",
"value": 20000000
},
{
"currency_/_unit": "USD",
"end_character": 29,
"end_date_for_period": "2022-01-31",
"label": "XBRL-OOS",
"start_character": 28,
"start_date_for_period": "2021-11-01",
"value": 3000000
}
] |
10-Q | 0000858877-23-000005 | 20230221163605 | 20230128 | CISCO SYSTEMS, INC. | Our operating lease income was $18 million and $39 million for the second quarter and first six months of fiscal 2023, respectively, and $29 million and $61 million for the corresponding periods of fiscal 2022, respectively, and was included in product revenue in the Consolidated Statement of Operations. | [
{
"currency_/_unit": "USD",
"end_character": 34,
"end_date_for_period": "2023-01-28",
"label": "revenues",
"start_character": 32,
"start_date_for_period": "2022-10-30",
"value": 18000000
},
{
"currency_/_unit": "USD",
"end_character": 50,
"end_date_for_period": "2023-01-28",
"label": "revenues",
"start_character": 48,
"start_date_for_period": "2022-07-31",
"value": 39000000
},
{
"currency_/_unit": "USD",
"end_character": 140,
"end_date_for_period": "2022-01-29",
"label": "revenues",
"start_character": 138,
"start_date_for_period": "2021-10-31",
"value": 29000000
},
{
"currency_/_unit": "USD",
"end_character": 156,
"end_date_for_period": "2022-01-29",
"label": "revenues",
"start_character": 154,
"start_date_for_period": "2021-08-01",
"value": 61000000
}
] |
10-Q | 0000896878-23-000010 | 20230223161924 | 20230131 | INTUIT INC | We recorded a $70 million tax benefit on a pretax income of $30 million for the three months ended January 31, 2022. We recorded a $60 million tax benefit on a pretax income of $268 million for the six months ended January 31, 2022. Excluding discrete tax items primarily related to share-based compensation tax benefits including those mentioned above, our effective tax rate for both periods was approximately 25%. The difference from the federal statutory rate of 21% was primarily due to state income taxes and non-deductible share-based compensation, which were partially offset by the tax benefit we received from the federal research and experimentation credit. | [
{
"currency_/_unit": "USD",
"end_character": 17,
"end_date_for_period": "2022-01-31",
"label": "XBRL-OOS",
"start_character": 15,
"start_date_for_period": "2021-11-01",
"value": -70000000
},
{
"currency_/_unit": "USD",
"end_character": 63,
"end_date_for_period": "2022-01-31",
"label": "earnings",
"start_character": 61,
"start_date_for_period": "2021-11-01",
"value": 30000000
},
{
"currency_/_unit": "USD",
"end_character": 134,
"end_date_for_period": "2022-01-31",
"label": "XBRL-OOS",
"start_character": 132,
"start_date_for_period": "2021-08-01",
"value": -60000000
},
{
"currency_/_unit": "USD",
"end_character": 181,
"end_date_for_period": "2022-01-31",
"label": "earnings",
"start_character": 178,
"start_date_for_period": "2021-08-01",
"value": 268000000
}
] |
10-Q | 0001493152-23-005672 | 20230221164609 | 20221231 | PHI GROUP INC | As
shown in the accompanying consolidated financial statements, the Company has accumulated deficit of $74,155,929 as of December 31, 2022
and total stockholders’ deficit of $6,881,906. For the quarter ended December 31, 2022, the Company incurred a net loss of $616,943
as compared to a net loss of $10,591,638 during the same period ended December 31, 2021. These factors as well as the uncertain conditions
that the Company faces in its day-to-day operations with respect to cash flows create an uncertainty as to the Company’s ability
to continue as a going concern. The financial statements do not include any adjustments that might be necessary should the Company be
unable to continue as a going concern. Management has taken action to strengthen the Company’s working capital position and generate
sufficient cash to meet its operating needs through June 30, 2023 and beyond. | [
{
"currency_/_unit": "USD",
"end_character": 270,
"end_date_for_period": "2022-12-31",
"label": "earnings",
"start_character": 263,
"start_date_for_period": "2022-10-01",
"value": -616943
},
{
"currency_/_unit": "USD",
"end_character": 311,
"end_date_for_period": "2021-12-31",
"label": "earnings",
"start_character": 301,
"start_date_for_period": "2021-10-01",
"value": -10591638
}
] |
10-Q | 0001213900-23-019981 | 20230314164509 | 20230131 | Rafael Holdings, Inc. | During
the three months ended January 31, 2023 and 2022, the Company recognized an income tax provision of $5 thousand on loss from continuing
operations before income tax of $3.2 million, and $4 thousand on a loss from continuing operations before income tax of $2.1 million,
respectively. During the six months ended January 31, 2023 and 2022, the Company recognized an income tax provision of $10 thousand on
loss from continuing operations before income tax of $8.4 million, and $4 thousand on a loss from continuing operations before income
tax of $130.3 million, respectively. The change in income tax expense in relation to the loss before income tax during the three and
six months ended January 31, 2023 compared to the three and six months ended January 31, 2022 was primarily due to differences in the
amount of taxable (loss) income in the various taxing jurisdictions and the associated valuation allowances. As of January 31, 2023 and
2022, the Company recorded valuation allowances for the total deferred tax asset balances. | [
{
"currency_/_unit": "USD",
"end_character": 109,
"end_date_for_period": "2023-01-31",
"label": "XBRL-OOS",
"start_character": 108,
"start_date_for_period": "2022-11-01",
"value": 5000
},
{
"currency_/_unit": "USD",
"end_character": 179,
"end_date_for_period": "2022-01-31",
"label": "XBRL-OOS",
"start_character": 176,
"start_date_for_period": "2021-11-01",
"value": 3200000
},
{
"currency_/_unit": "USD",
"end_character": 195,
"end_date_for_period": "2023-01-31",
"label": "earnings",
"start_character": 194,
"start_date_for_period": "2022-11-01",
"value": 4000
},
{
"currency_/_unit": "USD",
"end_character": 267,
"end_date_for_period": "2022-01-31",
"label": "earnings",
"start_character": 264,
"start_date_for_period": "2021-11-01",
"value": 2100000
},
{
"currency_/_unit": "USD",
"end_character": 399,
"end_date_for_period": "2023-01-31",
"label": "XBRL-OOS",
"start_character": 397,
"start_date_for_period": "2022-08-01",
"value": 10000
},
{
"currency_/_unit": "USD",
"end_character": 469,
"end_date_for_period": "2022-01-31",
"label": "XBRL-OOS",
"start_character": 466,
"start_date_for_period": "2021-08-01",
"value": 8400000
},
{
"currency_/_unit": "USD",
"end_character": 485,
"end_date_for_period": "2023-01-31",
"label": "earnings",
"start_character": 484,
"start_date_for_period": "2022-11-01",
"value": 4000
},
{
"currency_/_unit": "USD",
"end_character": 559,
"end_date_for_period": "2022-01-31",
"label": "earnings",
"start_character": 554,
"start_date_for_period": "2021-08-01",
"value": 130300000.00000001
}
] |
10-Q | 0001513162-23-000005 | 20230113165550 | 20221130 | BIOMERICA INC | Consolidated net sales were approximately $1,482,000 and $4,647,000 for the three months ended November 30, 2022 and 2021, respectively, and approximately $3,119,000 and $5,909,000 for the six months ended November 30, 2022 and 2021, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 52,
"end_date_for_period": "2022-11-30",
"label": "revenues",
"start_character": 43,
"start_date_for_period": "2022-09-01",
"value": 1482000
},
{
"currency_/_unit": "USD",
"end_character": 67,
"end_date_for_period": "2021-11-30",
"label": "revenues",
"start_character": 58,
"start_date_for_period": "2021-09-01",
"value": 4647000
},
{
"currency_/_unit": "USD",
"end_character": 166,
"end_date_for_period": "2022-11-30",
"label": "revenues",
"start_character": 157,
"start_date_for_period": "2022-06-01",
"value": 3119000
},
{
"currency_/_unit": "USD",
"end_character": 181,
"end_date_for_period": "2021-11-30",
"label": "revenues",
"start_character": 172,
"start_date_for_period": "2021-06-01",
"value": 5909000
}
] |
10-Q | 0001049521-23-000005 | 20230207163607 | 20221230 | MERCURY SYSTEMS INC | The Company recorded an income tax benefit of $2,151 and $155 on a loss before income taxes of $13,071 and $2,794 for the second quarters ended December 30, 2022 and December 31, 2021, respectively. The Company recorded an income tax benefit of $3,173 and $596 on a loss before income taxes of $28,428 and $10,375 for the six months ended December 30, 2022 and December 31, 2021, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 52,
"end_date_for_period": "2022-12-30",
"label": "XBRL-OOS",
"start_character": 47,
"start_date_for_period": "2022-10-01",
"value": -2151000
},
{
"currency_/_unit": "USD",
"end_character": 61,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 58,
"start_date_for_period": "2021-10-02",
"value": -155000
},
{
"currency_/_unit": "USD",
"end_character": 102,
"end_date_for_period": "2022-12-30",
"label": "earnings",
"start_character": 96,
"start_date_for_period": "2022-10-01",
"value": -13071000
},
{
"currency_/_unit": "USD",
"end_character": 113,
"end_date_for_period": "2021-12-31",
"label": "earnings",
"start_character": 108,
"start_date_for_period": "2021-10-02",
"value": -2794000
},
{
"currency_/_unit": "USD",
"end_character": 251,
"end_date_for_period": "2022-12-30",
"label": "XBRL-OOS",
"start_character": 246,
"start_date_for_period": "2022-07-02",
"value": -3173000
},
{
"currency_/_unit": "USD",
"end_character": 260,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 257,
"start_date_for_period": "2021-07-03",
"value": -596000
},
{
"currency_/_unit": "USD",
"end_character": 301,
"end_date_for_period": "2022-12-30",
"label": "earnings",
"start_character": 295,
"start_date_for_period": "2022-07-02",
"value": -28428000
},
{
"currency_/_unit": "USD",
"end_character": 313,
"end_date_for_period": "2021-12-31",
"label": "earnings",
"start_character": 307,
"start_date_for_period": "2021-07-03",
"value": -10375000
}
] |
10-Q | 0001618921-23-000019 | 20230328160108 | 20230228 | Walgreens Boots Alliance, Inc. | Due to the anti-dilutive effect resulting from the reported net loss, an incremental 4.8 million of potentially dilutive securities were omitted from the calculation of weighted-average common shares outstanding for the six months ended February 28, 2023. | [
{
"currency_/_unit": "shares",
"end_character": 88,
"end_date_for_period": "2023-02-28",
"label": "eps",
"start_character": 85,
"start_date_for_period": "2022-09-01",
"value": 4800000
}
] |
10-Q | 0001504461-23-000010 | 20230209164941 | 20221231 | NGL Energy Partners LP | Our lessor arrangements include storage and railcar contracts. We also, from time to time, sublease certain of our storage capacity and railcars to third-parties. Fixed rental revenue is recognized on a straight-line basis over the lease term. During the three months ended December 31, 2022 and 2021, fixed rental revenue was $4.5 million, which includes $2.3 million of sublease revenue, and $3.7 million, which includes $0.5 million of sublease revenue, respectively. During the nine months ended December 31, 2022 and 2021, fixed rental revenue was $11.2 million, which includes $3.4 million of sublease revenue and $10.9 million, which includes $1.1 million of sublease revenue, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 331,
"end_date_for_period": "2022-12-31",
"label": "revenues",
"start_character": 328,
"start_date_for_period": "2022-10-01",
"value": 4500000
},
{
"currency_/_unit": "USD",
"end_character": 360,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 357,
"start_date_for_period": "2022-10-01",
"value": 2300000
},
{
"currency_/_unit": "USD",
"end_character": 398,
"end_date_for_period": "2021-12-31",
"label": "revenues",
"start_character": 395,
"start_date_for_period": "2021-10-01",
"value": 3700000
},
{
"currency_/_unit": "USD",
"end_character": 427,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 424,
"start_date_for_period": "2021-10-01",
"value": 500000
},
{
"currency_/_unit": "USD",
"end_character": 558,
"end_date_for_period": "2022-12-31",
"label": "revenues",
"start_character": 554,
"start_date_for_period": "2022-04-01",
"value": 11200000
},
{
"currency_/_unit": "USD",
"end_character": 587,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 584,
"start_date_for_period": "2022-04-01",
"value": 3400000
},
{
"currency_/_unit": "USD",
"end_character": 625,
"end_date_for_period": "2021-12-31",
"label": "revenues",
"start_character": 621,
"start_date_for_period": "2021-04-01",
"value": 10900000
},
{
"currency_/_unit": "USD",
"end_character": 654,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 651,
"start_date_for_period": "2021-04-01",
"value": 1100000
}
] |
10-Q | 0001062993-23-001003 | 20230117170248 | 20221130 | Salona Global Medical Device Corp | Since acquisition, Mio-Guard has generated $5,198,062 of revenue and has generated net earnings before tax of $281,357. These amounts are included in the unaudited interim condensed consolidated statements of operations and comprehensive loss. If the combination had taken place at the beginning of the year, Mio-Guard's revenue would have been $5,263,365 and profit before tax would have been $250,381. If the combination had taken place at the beginning of the year, consolidated revenues would have been $35,903,804 and consolidated losses before tax would have been ($14,227,449). The pro forma unaudited results include estimates and assumptions which management believes are reasonable. These assumptions include an adjustment to operating income for one-time transactional costs that would not have occurred without the acquisition of Mio-Guard. Additionally, the pro forma results do not include any cost savings or other effects of the planned integration of these entities and may not be fully indicative of the results that would have occurred if the business combination had been in effect on the dates indicated. | [
{
"currency_/_unit": "CAD",
"end_character": 53,
"end_date_for_period": "2022-11-30",
"label": "revenues",
"start_character": 44,
"start_date_for_period": "2022-03-01",
"value": 5198062
},
{
"currency_/_unit": "CAD",
"end_character": 118,
"end_date_for_period": "2022-11-30",
"label": "earnings",
"start_character": 111,
"start_date_for_period": "2022-03-01",
"value": 281357
},
{
"currency_/_unit": "CAD",
"end_character": 355,
"end_date_for_period": "2022-03-11",
"label": "revenues",
"start_character": 346,
"start_date_for_period": "2022-03-01",
"value": 5263365
},
{
"currency_/_unit": "CAD",
"end_character": 402,
"end_date_for_period": "2022-03-11",
"label": "earnings",
"start_character": 395,
"start_date_for_period": "2022-03-01",
"value": 250381
},
{
"currency_/_unit": "CAD",
"end_character": 519,
"end_date_for_period": "2022-03-11",
"label": "revenues",
"start_character": 508,
"start_date_for_period": "2022-03-01",
"value": 35903804
},
{
"currency_/_unit": "CAD",
"end_character": 583,
"end_date_for_period": "2022-03-11",
"label": "earnings",
"start_character": 573,
"start_date_for_period": "2022-03-01",
"value": -14227449
}
] |
10-Q | 0001062993-23-001003 | 20230117170248 | 20221130 | Salona Global Medical Device Corp | Since acquisition, Mio-Guard has generated $5,198,062 of revenue and has generated net earnings before tax of $281,357. These amounts are included in the unaudited interim condensed consolidated statements of operations and comprehensive loss. If the combination had taken place at the beginning of the year, Mio-Guard's revenue would have been $5,263,365 and profit before tax would have been $250,381. If the combination had taken place at the beginning of the year, consolidated revenues would have been $35,903,804 and consolidated losses before tax would have been ($14,227,449). The pro forma unaudited results include estimates and assumptions which management believes are reasonable. These assumptions include an adjustment to operating income for one-time transactional costs that would not have occurred without the acquisition of Mio-Guard. Additionally, the pro forma results do not include any cost savings or other effects of the planned integration of these entities and may not be fully indicative of the results that would have occurred if the business combination had been in effect on the dates indicated. | [
{
"currency_/_unit": "CAD",
"end_character": 53,
"end_date_for_period": "2022-11-30",
"label": "revenues",
"start_character": 44,
"start_date_for_period": "2022-03-01",
"value": 5198062
},
{
"currency_/_unit": "CAD",
"end_character": 118,
"end_date_for_period": "2022-11-30",
"label": "earnings",
"start_character": 111,
"start_date_for_period": "2022-03-01",
"value": 281357
},
{
"currency_/_unit": "CAD",
"end_character": 355,
"end_date_for_period": "2022-03-11",
"label": "revenues",
"start_character": 346,
"start_date_for_period": "2022-03-01",
"value": 5263365
},
{
"currency_/_unit": "CAD",
"end_character": 402,
"end_date_for_period": "2022-03-11",
"label": "earnings",
"start_character": 395,
"start_date_for_period": "2022-03-01",
"value": 250381
},
{
"currency_/_unit": "CAD",
"end_character": 519,
"end_date_for_period": "2022-03-11",
"label": "revenues",
"start_character": 508,
"start_date_for_period": "2022-03-01",
"value": 35903804
},
{
"currency_/_unit": "CAD",
"end_character": 583,
"end_date_for_period": "2022-03-11",
"label": "earnings",
"start_character": 573,
"start_date_for_period": "2022-03-01",
"value": -14227449
}
] |
10-Q | 0001062993-23-001003 | 20230117170248 | 20221130 | Salona Global Medical Device Corp | Since acquisition, DaMar has generated $1,528,558 of revenue and has generated net earnings before tax of $220,403. These amounts are included in the unaudited interim condensed consolidated statements of operations and comprehensive loss. If the combination had taken place at the beginning of the year, DaMar's revenue would have been $5,816,513 and profit before tax would have been $1,092,984. If the combination had taken place at the beginning of the year, consolidated revenues would have been $36,456,952 and consolidated losses before tax would have been ($13,384,846). The pro forma unaudited results include estimates and assumptions which management believes are reasonable. These assumptions include an adjustment to operating income for one-time transactional costs that would not have occurred without the acquisition of DaMar. Additionally, the pro forma results do not include any cost savings or other effects of the planned integration of these entities and may not be fully indicative of the results that would have occurred if the business combination had been in effect on the dates indicated. | [
{
"currency_/_unit": "CAD",
"end_character": 49,
"end_date_for_period": "2022-11-30",
"label": "revenues",
"start_character": 40,
"start_date_for_period": "2022-03-01",
"value": 1528558
},
{
"currency_/_unit": "CAD",
"end_character": 114,
"end_date_for_period": "2022-11-30",
"label": "earnings",
"start_character": 107,
"start_date_for_period": "2022-03-01",
"value": 220403
},
{
"currency_/_unit": "CAD",
"end_character": 347,
"end_date_for_period": "2022-09-23",
"label": "revenues",
"start_character": 338,
"start_date_for_period": "2022-09-01",
"value": 5816513
},
{
"currency_/_unit": "CAD",
"end_character": 396,
"end_date_for_period": "2022-09-23",
"label": "earnings",
"start_character": 387,
"start_date_for_period": "2022-09-01",
"value": 1092984
},
{
"currency_/_unit": "CAD",
"end_character": 512,
"end_date_for_period": "2022-09-23",
"label": "revenues",
"start_character": 502,
"start_date_for_period": "2022-09-01",
"value": 36456952
},
{
"currency_/_unit": "CAD",
"end_character": 576,
"end_date_for_period": "2022-09-23",
"label": "earnings",
"start_character": 566,
"start_date_for_period": "2022-09-01",
"value": -13384846
}
] |
10-Q | 0001062993-23-001003 | 20230117170248 | 20221130 | Salona Global Medical Device Corp | Since acquisition, DaMar has generated $1,528,558 of revenue and has generated net earnings before tax of $220,403. These amounts are included in the unaudited interim condensed consolidated statements of operations and comprehensive loss. If the combination had taken place at the beginning of the year, DaMar's revenue would have been $5,816,513 and profit before tax would have been $1,092,984. If the combination had taken place at the beginning of the year, consolidated revenues would have been $36,456,952 and consolidated losses before tax would have been ($13,384,846). The pro forma unaudited results include estimates and assumptions which management believes are reasonable. These assumptions include an adjustment to operating income for one-time transactional costs that would not have occurred without the acquisition of DaMar. Additionally, the pro forma results do not include any cost savings or other effects of the planned integration of these entities and may not be fully indicative of the results that would have occurred if the business combination had been in effect on the dates indicated. | [
{
"currency_/_unit": "CAD",
"end_character": 49,
"end_date_for_period": "2022-11-30",
"label": "revenues",
"start_character": 40,
"start_date_for_period": "2022-03-01",
"value": 1528558
},
{
"currency_/_unit": "CAD",
"end_character": 114,
"end_date_for_period": "2022-11-30",
"label": "earnings",
"start_character": 107,
"start_date_for_period": "2022-03-01",
"value": 220403
},
{
"currency_/_unit": "CAD",
"end_character": 347,
"end_date_for_period": "2022-09-23",
"label": "revenues",
"start_character": 338,
"start_date_for_period": "2022-09-01",
"value": 5816513
},
{
"currency_/_unit": "CAD",
"end_character": 396,
"end_date_for_period": "2022-09-23",
"label": "earnings",
"start_character": 387,
"start_date_for_period": "2022-09-01",
"value": 1092984
},
{
"currency_/_unit": "CAD",
"end_character": 512,
"end_date_for_period": "2022-09-23",
"label": "revenues",
"start_character": 502,
"start_date_for_period": "2022-09-01",
"value": 36456952
},
{
"currency_/_unit": "CAD",
"end_character": 576,
"end_date_for_period": "2022-09-23",
"label": "earnings",
"start_character": 566,
"start_date_for_period": "2022-09-01",
"value": -13384846
}
] |
10-Q | 0001493152-23-005319 | 20230216155603 | 20221231 | NaturalShrimp Inc | The
accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally
accepted in the United States of America (“GAAP”), assuming the Company will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. For the nine months ended December 31, 2022,
the Company had a net loss from operations of approximately $8,609,000 | [
{
"currency_/_unit": "USD",
"end_character": 473,
"end_date_for_period": "2022-12-31",
"label": "ebit",
"start_character": 464,
"start_date_for_period": "2022-04-01",
"value": -8609000
}
] |
10-Q | 0001143513-23-000003 | 20230206160704 | 20221231 | GLADSTONE CAPITAL CORP | Gladstone Securities, LLC (“Gladstone Securities”), a privately-held broker-dealer registered with the Financial Industry Regulatory Authority and insured by the Securities Investor Protection Corporation, which is 100% indirectly owned and controlled by Mr. Gladstone, our chairman and chief executive officer, has provided other services, such as investment banking and due diligence services, to certain of our portfolio companies, for which Gladstone Securities receives a fee. Any such fees paid by portfolio companies to Gladstone Securities do not impact the fees we pay to the Adviser or the non-contractual, unconditional and irrevocable credits against the base management fee or incentive fee. Gladstone Securities received fees from portfolio companies totaling $16 thousand and $0.6 million during the three months ended December 31, 2022 and 2021, respectively. | [
{
"currency_/_unit": "pure",
"end_character": 218,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 215,
"start_date_for_period": "2022-12-31",
"value": 1
},
{
"currency_/_unit": "USD",
"end_character": 777,
"end_date_for_period": "2022-12-31",
"label": "revenues",
"start_character": 775,
"start_date_for_period": "2022-10-01",
"value": 16000
},
{
"currency_/_unit": "USD",
"end_character": 795,
"end_date_for_period": "2021-12-31",
"label": "revenues",
"start_character": 792,
"start_date_for_period": "2021-10-01",
"value": 600000
}
] |
10-Q | 0001493152-23-003538 | 20230203164545 | 20220930 | PHI GROUP INC | As
shown in the accompanying consolidated financial statements, the Company has accumulated deficit of $73,538,986 as of September 30, 2022
and total stockholders’ deficit of $6,267,628. For the quarter ended September 30, 2022, the Company incurred a net loss of $1,821,013
as compared to a net loss of $5,960,170 during the same period ended September 30, 2021. These factors as well as the uncertain conditions
that the Company faces in its day-to-day operations with respect to cash flows create an uncertainty as to the Company’s ability
to continue as a going concern. The financial statements do not include any adjustments that might be necessary should the Company be
unable to continue as a going concern. Management has taken action to strengthen the Company’s working capital position and generate
sufficient cash to meet its operating needs through June 30, 2023 and beyond. | [
{
"currency_/_unit": "USD",
"end_character": 274,
"end_date_for_period": "2022-09-30",
"label": "earnings",
"start_character": 265,
"start_date_for_period": "2022-07-01",
"value": -1821013
},
{
"currency_/_unit": "USD",
"end_character": 314,
"end_date_for_period": "2021-09-30",
"label": "earnings",
"start_character": 305,
"start_date_for_period": "2021-07-01",
"value": -5960170
}
] |
10-Q | 0001213900-23-010756 | 20230213163053 | 20221231 | DATASEA INC. | During
the six and three months ended December 31, 2022, the Company’s revenue of $1.45 million and $0.41 million was
mainly from 5G messaging services includ | [
{
"currency_/_unit": "USD",
"end_character": 87,
"end_date_for_period": "2022-12-31",
"label": "revenues",
"start_character": 83,
"start_date_for_period": "2022-07-01",
"value": 1450000
},
{
"currency_/_unit": "USD",
"end_character": 105,
"end_date_for_period": "2022-12-31",
"label": "revenues",
"start_character": 101,
"start_date_for_period": "2022-10-01",
"value": 410000
}
] |
10-Q | 0001607062-23-000092 | 20230214164449 | 20221231 | VERITEC INC | On
March 26, 2022, as amended on May 10, 2022, the Company and Es Solo Holdings Ltd (“Es Solo”), an England & Wales limited
liability company, entered into a Prepaid Card Client Program Management Agreement (“Management Agreement”). Es Solo
develops, markets, and operates prepaid card programs through its affiliations with issuing banks, and the Company desires to have Es
Solo develop a prepaid card program to be marketed by the Company for card issuing purposes, pursuant to the terms of the Management Agreement.
Es Solo agreed to pay the Company $10,000 as a program setup fee. The Company and Es Solo agreed to a 50%/50% revenue share arrangement
based on fees collected from customers using the Company’s prepaid, Bio-ID, and debit card products. As of December 31, 2022,
no revenues have been realized under the Management Agreement. | [
{
"currency_/_unit": "USD",
"end_character": 561,
"end_date_for_period": "2022-05-10",
"label": "XBRL-OOS",
"start_character": 555,
"start_date_for_period": "2022-05-01",
"value": 10000
},
{
"currency_/_unit": "USD",
"end_character": 785,
"end_date_for_period": "2022-12-31",
"label": "revenues",
"start_character": 783,
"start_date_for_period": "2022-07-01",
"value": 0
}
] |
10-Q | 0001262976-23-000007 | 20230126170710 | 20221231 | CIMPRESS plc | (2) On May 1, 2020, we entered into a financing arrangement with Apollo Global Management, Inc., which included 7-year warrants with a strike price of $60 that have a potentially dilutive impact on our weighted average shares outstanding. For the three and six months ended December 31, 2022, the weighted average anti-dilutive effect of the warrants was 1,055,377 shares in both periods, and 281,884 and 345,722 shares for the three and six months ended December 31, 2021, respectively. | [
{
"currency_/_unit": null,
"end_character": 154,
"end_date_for_period": "2020-05-01",
"label": "XBRL-OOS",
"start_character": 152,
"start_date_for_period": "2020-05-01",
"value": 60
},
{
"currency_/_unit": "shares",
"end_character": 364,
"end_date_for_period": "2022-12-31",
"label": "eps",
"start_character": 355,
"start_date_for_period": "2022-10-01",
"value": 1055377
},
{
"currency_/_unit": "shares",
"end_character": 400,
"end_date_for_period": "2021-12-31",
"label": "eps",
"start_character": 393,
"start_date_for_period": "2021-10-01",
"value": 281884
},
{
"currency_/_unit": "shares",
"end_character": 412,
"end_date_for_period": "2021-12-31",
"label": "eps",
"start_character": 405,
"start_date_for_period": "2021-07-01",
"value": 345722
}
] |
10-Q | 0000785557-23-000026 | 20230208163140 | 20221231 | DLH Holdings Corp. | During the three months ended December 31, 2022 following the completion of the acquisition, GRSi contributed approximately $6.9 million of revenue and $0.3 million of income from operations. | [
{
"currency_/_unit": "USD",
"end_character": 128,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 125,
"start_date_for_period": "2022-10-01",
"value": 6900000
},
{
"currency_/_unit": "USD",
"end_character": 156,
"end_date_for_period": "2022-12-31",
"label": "ebit",
"start_character": 153,
"start_date_for_period": "2022-10-01",
"value": 300000
}
] |
10-Q | 0001628280-23-002819 | 20230208185355 | 20221231 | CANTALOUPE, INC. | The amount of 32M revenue included in the Company’s Condensed Consolidated Statement of Operations from the acquisition date through December 31, 2022 was $1.3 million. The amount of 32M earnings included in the Company’s Condensed Consolidated Statement of Operations from the acquisition date through December 31, 2022 was $0.1 million. | [
{
"currency_/_unit": "USD",
"end_character": 159,
"end_date_for_period": "2022-12-31",
"label": "revenues",
"start_character": 156,
"start_date_for_period": "2022-12-01",
"value": 1300000
},
{
"currency_/_unit": "USD",
"end_character": 329,
"end_date_for_period": "2022-12-31",
"label": "earnings",
"start_character": 326,
"start_date_for_period": "2022-12-01",
"value": 100000
}
] |
10-Q | 0001443646-23-000021 | 20230127064819 | 20221231 | Booz Allen Hamilton Holding Corp | During the three months ended December 31, 2022 and 2021, approximately 1.1 million and 1.0 million participating securities were paid dividends totaling $0.5 million and $0.4 million, respectively. During the nine months ended December 31, 2022 and 2021, approximately 1.0 million and 0.9 million participating securities were paid dividends totaling $1.3 million and $1.0 million, respectively. There were undistributed earnings of $— million | [
{
"currency_/_unit": "shares",
"end_character": 75,
"end_date_for_period": "2022-12-31",
"label": "eps",
"start_character": 72,
"start_date_for_period": "2022-10-01",
"value": 1100000
},
{
"currency_/_unit": "shares",
"end_character": 91,
"end_date_for_period": "2021-12-31",
"label": "eps",
"start_character": 88,
"start_date_for_period": "2021-10-01",
"value": 1000000
},
{
"currency_/_unit": "USD",
"end_character": 158,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 155,
"start_date_for_period": "2022-10-01",
"value": 500000
},
{
"currency_/_unit": "USD",
"end_character": 175,
"end_date_for_period": "2021-12-31",
"label": "XBRL-OOS",
"start_character": 172,
"start_date_for_period": "2021-10-01",
"value": 400000
},
{
"currency_/_unit": "shares",
"end_character": 273,
"end_date_for_period": "2021-12-31",
"label": "eps",
"start_character": 270,
"start_date_for_period": "2021-10-01",
"value": 1000000
},
{
"currency_/_unit": "shares",
"end_character": 289,
"end_date_for_period": "2021-12-31",
"label": "eps",
"start_character": 286,
"start_date_for_period": "2021-04-01",
"value": 900000
},
{
"currency_/_unit": "USD",
"end_character": 356,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 353,
"start_date_for_period": "2022-04-01",
"value": 1300000
},
{
"currency_/_unit": "shares",
"end_character": 373,
"end_date_for_period": "2021-12-31",
"label": "eps",
"start_character": 370,
"start_date_for_period": "2021-10-01",
"value": 1000000
}
] |
10-Q | 0000107140-23-000034 | 20230310130357 | 20230131 | JOHN WILEY & SONS, INC. | XYZ Media’s incremental revenue and operating loss included in our Academic segment results for the three months ended January 31, 2023 was $1.5 million and $(0.8) million, respectively. XYZ Media’s incremental revenue and operating loss included in our Academic segment results for the nine months ended January 31, 2023 was $6.9 million and $(3.1) million, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 144,
"end_date_for_period": "2023-01-31",
"label": "XBRL-OOS",
"start_character": 141,
"start_date_for_period": "2022-11-01",
"value": 1500000
},
{
"currency_/_unit": "USD",
"end_character": 162,
"end_date_for_period": "2023-01-31",
"label": "ebit",
"start_character": 159,
"start_date_for_period": "2022-11-01",
"value": -800000
},
{
"currency_/_unit": "USD",
"end_character": 330,
"end_date_for_period": "2023-01-31",
"label": "XBRL-OOS",
"start_character": 327,
"start_date_for_period": "2022-05-01",
"value": 6900000
},
{
"currency_/_unit": "USD",
"end_character": 348,
"end_date_for_period": "2023-01-31",
"label": "ebit",
"start_character": 345,
"start_date_for_period": "2022-05-01",
"value": -3100000
}
] |
10-Q | 0000107140-23-000034 | 20230310130357 | 20230131 | JOHN WILEY & SONS, INC. | The incremental revenue and operating loss included in the Research segment for the three months ended January 31, 2023 related to these other acquisitions was approximately $0.7 million and $(0.2) million, respectively. The incremental revenue and operating loss included in the Research segment for the nine months ended January 31, 2023 related to these other acquisitions was approximately $9.3 million and $(2.2) million, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 178,
"end_date_for_period": "2023-01-31",
"label": "XBRL-OOS",
"start_character": 175,
"start_date_for_period": "2022-11-01",
"value": 700000
},
{
"currency_/_unit": "USD",
"end_character": 196,
"end_date_for_period": "2023-01-31",
"label": "ebit",
"start_character": 193,
"start_date_for_period": "2022-11-01",
"value": -200000
},
{
"currency_/_unit": "USD",
"end_character": 398,
"end_date_for_period": "2023-01-31",
"label": "XBRL-OOS",
"start_character": 395,
"start_date_for_period": "2022-05-01",
"value": 9300000
},
{
"currency_/_unit": "USD",
"end_character": 416,
"end_date_for_period": "2023-01-31",
"label": "ebit",
"start_character": 413,
"start_date_for_period": "2022-05-01",
"value": -2200000
}
] |
10-Q | 0000023197-23-000019 | 20230309163323 | 20230131 | COMTECH TELECOMMUNICATIONS CORP /DE/ | Weighted average stock options, RSUs and restricted stock outstanding of 967,000 and 1,467,000 for the three months ended January 31, 2023 and 2022, respectively, and 1,023,000 and 1,498,000 shares for the six months ended January 31, 2023 and 2022, respectively, were not included in our diluted EPS calculation because their effect would have been anti-dilutive. Our EPS calculations exclude 431,000 and 273,000 weighted average performance shares outstanding for the three months ended January 31, 2023 and 2022, respectively, and 352,000 and 258,000 for the six months ended January 31, 2023 and 2022, respectively, as the performance conditions have not yet been satisfied. However, the numerator for EPS calculations for each respective period is reduced by the compensation expense related to these awards. | [
{
"currency_/_unit": "shares",
"end_character": 80,
"end_date_for_period": "2023-01-31",
"label": "XBRL-OOS",
"start_character": 73,
"start_date_for_period": "2022-11-01",
"value": 967000
},
{
"currency_/_unit": "shares",
"end_character": 94,
"end_date_for_period": "2022-01-31",
"label": "XBRL-OOS",
"start_character": 85,
"start_date_for_period": "2021-11-01",
"value": 1467000
},
{
"currency_/_unit": "shares",
"end_character": 176,
"end_date_for_period": "2023-01-31",
"label": "XBRL-OOS",
"start_character": 167,
"start_date_for_period": "2022-08-01",
"value": 1023000
},
{
"currency_/_unit": "shares",
"end_character": 190,
"end_date_for_period": "2022-01-31",
"label": "XBRL-OOS",
"start_character": 181,
"start_date_for_period": "2021-08-01",
"value": 1498000
},
{
"currency_/_unit": "shares",
"end_character": 401,
"end_date_for_period": "2023-01-31",
"label": "eps",
"start_character": 394,
"start_date_for_period": "2022-11-01",
"value": 431000
},
{
"currency_/_unit": "shares",
"end_character": 413,
"end_date_for_period": "2022-01-31",
"label": "eps",
"start_character": 406,
"start_date_for_period": "2021-11-01",
"value": 273000
},
{
"currency_/_unit": "shares",
"end_character": 541,
"end_date_for_period": "2023-01-31",
"label": "eps",
"start_character": 534,
"start_date_for_period": "2022-08-01",
"value": 352000
},
{
"currency_/_unit": "shares",
"end_character": 553,
"end_date_for_period": "2022-01-31",
"label": "eps",
"start_character": 546,
"start_date_for_period": "2021-08-01",
"value": 258000
}
] |
10-Q | 0001213900-23-001829 | 20230110070054 | 20221130 | TSR INC | Basic
net income per common share is computed by dividing net income available to common stockholders of TSR, Inc. by the weighted average
number of common shares outstanding during the reporting period, excluding the effects of any potentially dilutive securities. During
the quarter ended February 28, 2021, the Company granted time and performance vesting restricted stock awards under its 2020 Equity Incentive
Plan (see Note 16 for further information). Diluted earnings per share gives effect to all potentially dilutive common shares outstanding
during the reporting period. The common stock equivalents associated with these restricted stock awards of 92,471, 91,318, 70,816, and
62,015 have been included for dilutive shares outstanding for the three and six months ended November 30, 2022 and 2021, respectively. | [
{
"currency_/_unit": "shares",
"end_character": 666,
"end_date_for_period": "2022-11-30",
"label": "eps",
"start_character": 660,
"start_date_for_period": "2022-09-01",
"value": 92471
},
{
"currency_/_unit": "shares",
"end_character": 674,
"end_date_for_period": "2021-11-30",
"label": "eps",
"start_character": 668,
"start_date_for_period": "2021-09-01",
"value": 91318
},
{
"currency_/_unit": "shares",
"end_character": 682,
"end_date_for_period": "2022-11-30",
"label": "eps",
"start_character": 676,
"start_date_for_period": "2022-06-01",
"value": 70816
},
{
"currency_/_unit": "shares",
"end_character": 694,
"end_date_for_period": "2021-11-30",
"label": "eps",
"start_character": 688,
"start_date_for_period": "2021-06-01",
"value": 62015
}
] |
10-Q | 0001493152-23-008949 | 20230324175159 | 20221231 | AG Acquisition Group III, Inc. | Since
the inception of the Company through December 31, 2022, the Company has not generated cash or revenue. For the three and six months
ended December 31, 2022, the Company incurred a net loss of $6,688
and $10,500,
respectively. For the six months ended December 31, 2022, the Company used net cash in operations of $6,475.
The Company had working capital deficiency of $290
as of December 31, 2022. The Company’s continuation as a going concern is dependent on its ability to obtain additional
financing from its stockholders or other sources, as may be required, to meet is financial obligations as they become
due. | [
{
"currency_/_unit": "USD",
"end_character": 204,
"end_date_for_period": "2022-12-31",
"label": "earnings",
"start_character": 199,
"start_date_for_period": "2022-10-01",
"value": -6688
},
{
"currency_/_unit": "USD",
"end_character": 216,
"end_date_for_period": "2022-12-31",
"label": "earnings",
"start_character": 210,
"start_date_for_period": "2022-07-01",
"value": -10500
},
{
"currency_/_unit": "USD",
"end_character": 325,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 320,
"start_date_for_period": "2022-07-01",
"value": -6475
},
{
"currency_/_unit": "USD",
"end_character": 377,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 374,
"start_date_for_period": "2022-12-31",
"value": 290
}
] |
10-Q | 0001493152-23-008847 | 20230324143521 | 20220930 | FOMO WORLDWIDE, INC. | On
February 27, 2023, the Company signed a letter of intent to purchase a provider of modular buildings and construction services generating
an estimated $10 million annual revenues and $1 million annual EBITDA in 2022. The Target’s customers include K12 schools, police
departments, fire departments, and municipalities in the state of Florida. There are no assurances FOMO will be able to complete the
transaction based on planned due diligence or required financing. | [
{
"currency_/_unit": "USD",
"end_character": 157,
"end_date_for_period": "2023-02-27",
"label": "revenues",
"start_character": 155,
"start_date_for_period": "2023-02-27",
"value": 10000000
},
{
"currency_/_unit": "USD",
"end_character": 188,
"end_date_for_period": "2023-02-27",
"label": "earnings",
"start_character": 187,
"start_date_for_period": "2023-02-27",
"value": 1000000
}
] |
10-Q | 0001493152-23-004872 | 20230214160647 | 20221231 | Glimpse Group, Inc. | The
Company incurred losses of $4.07 million and $3.23 million during the six months ended December 31, 2022 and 2021, respectively. These
losses were incurred as the Company funded operational expenses, primarily research and development, general and administrative, and
sales and marketing costs. | [
{
"currency_/_unit": "USD",
"end_character": 36,
"end_date_for_period": "2022-12-31",
"label": "earnings",
"start_character": 32,
"start_date_for_period": "2022-07-01",
"value": -4070000.0000000005
},
{
"currency_/_unit": "USD",
"end_character": 54,
"end_date_for_period": "2021-12-31",
"label": "earnings",
"start_character": 50,
"start_date_for_period": "2021-07-01",
"value": -3230000
}
] |
10-Q | 0001493152-23-004872 | 20230214160647 | 20221231 | Glimpse Group, Inc. | The
Company recognized approximately $2.55 million in revenue and $0.50 million (inclusive of contingent consideration fair value adjustment
gain of $1.58 million) of net income related to BLI since the acquisition Closing date of August 1, 2022 through December 31, 2022 in
the consolidated statement of operations. | [
{
"currency_/_unit": "USD",
"end_character": 42,
"end_date_for_period": "2022-12-31",
"label": "revenues",
"start_character": 38,
"start_date_for_period": "2022-08-01",
"value": 2550000
},
{
"currency_/_unit": "USD",
"end_character": 71,
"end_date_for_period": "2022-12-31",
"label": "earnings",
"start_character": 67,
"start_date_for_period": "2022-08-01",
"value": 500000
},
{
"currency_/_unit": "USD",
"end_character": 154,
"end_date_for_period": "2022-12-31",
"label": "XBRL-OOS",
"start_character": 150,
"start_date_for_period": "2022-08-01",
"value": 1580000
}
] |
Subsets and Splits